Animal Feed Probiotics Market Size & Share 2026-2035

Animal Feed Probiotics Market Size

The global animal feed probiotics market is estimated at USD 267.3 million in 2025. It is projected to reach USD 283.7 million in 2026, USD 372.37 million by 2030, and USD 551.2 million by 2035, expanding at a 7.7% CAGR during 2026-2035.

Demand is being shaped by livestock producers' need to manage gut health, feed conversion, pathogen pressure, and animal resilience as medically important antimicrobial use becomes more restricted.

The market includes live microbial preparations, yeast-based products, postbiotic derivatives, and other microbial feed additives for livestock, aquaculture, companion animals, and equines. Bacillus products retain a structural advantage in pelleted feed because endospores withstand heat and handling conditions that can impair more sensitive live cultures. Lactobacilli are more relevant in liquid-feeding, waterline, and premium pet-nutrition formats, while yeast products serve ruminant, aquaculture, and multifunctional gut-health applications. Postbiotics provide an alternative where live-cell authorization or viability creates a commercial constraint.

Poultry accounts for 38% of 2025 market value, or USD 100.95 million, followed by swine at 24% or USD 63.53 million and cattle and ruminants at 18% or USD 47.48 million. The largest regional market is Asia Pacific at USD 93.09 million in 2025, while Europe totals USD 80.99 million and North America USD 54.25 million. Europe's demand base is reinforced by Regulation (EU) 2019/4, which restricts prophylactic and growth-promoting antimicrobial use in medicated feed ^{[1]European Commission, eur-lex.europa.eu}. In the United States, the Veterinary Feed Directive framework eliminated growth-promotion labeling for medically important antimicrobials ^{[2]U.S. Food and Drug Administration, fda.gov}. Middle East and Africa, valued at USD 15.56 million in 2025, is projected to post the highest regional CAGR, at 9.61%.

The next phase of adoption will depend on whether viability technologies narrow the gap between controlled trial outcomes and commercial results. Heat-stable Bacillus products already fit conventional feed-mill infrastructure; microencapsulation and waterline delivery broaden the addressable strain pool by reducing losses during pelleting, storage, and gastrointestinal transit. This shifts competition toward demonstrable delivery performance and repeatable farm economics.

Key Drivers

Science-Backed Performance Gains in Feed Conversion, Gut Integrity, and Survival

The commercial case for probiotic inclusion is strongest where performance can be translated into feed-cost or mortality outcomes. A 2024 weaned-piglet study found that a probiotic control group achieved a feed conversion ratio of 1.543, compared with 1.654 for lower-dose combinations. In broilers, Pediococcus pentosaceus GT001 improved growth, feed intake, antioxidant indicators, and immune-related measures under a 42-day supplementation trial. Separate broiler work found that Bacillus licheniformis improved body weight and average daily gain while increasing jejunal villus height and barrier-related gene expression ^{[3]PubMed Central, pmc.ncbi.nlm.nih.gov}.

The evidence also extends into species where disease pressure has direct financial consequences. Bacillus subtilis BS9 delivered lower feed conversion ratios in nursery pigs while maintaining diarrhea outcomes comparable with pharmacological zinc oxide and reducing fecal E. coli counts. In feedlot cattle, Lactobacillus supplementation was associated with production and fecal-microbiology improvements over a 163-day trial. White-leg shrimp receiving a multispecies probiotic showed improved survival and specific growth rate, reduced feed conversion ratio, and lower mortality after Vibrio parahaemolyticus challenge. These results matter because they allow integrators to evaluate probiotics against operating metrics rather than treating them as a generalized wellness input.

Antimicrobial Stewardship and Export-Market Requirements

European regulation has created a durable compliance backdrop for non-antibiotic gut-health interventions. Regulation (EU) 2019/4 prohibits medicated-feed use of antimicrobials for prophylaxis and growth promotion. Commission Delegated Regulation (EU) 2024/1229 established maximum cross-contamination levels for 24 antimicrobial active substances in non-target feed, while Commission Implementing Regulation (EU) 2024/1973 restricts specified antimicrobial classes for food-producing animals. Together, these measures extend antimicrobial stewardship from on-farm use into feed-manufacturing controls.

In the United States, the Veterinary Feed Directive shifted remaining medically important antimicrobial uses to veterinary oversight and removed production-use claims. FDA Guidance for Industry #213 completed the withdrawal of growth-promotion conditions from 31 affected applications. The WOAH antimicrobial-resistance agenda, including the Muscat Manifesto objective to reduce agricultural and livestock antimicrobial use by 30% by 2030, reinforces the direction of travel across animal-production systems ^{[4]World Organisation for Animal Health, woah.org}. For suppliers serving export-oriented poultry, swine, and aquaculture customers, probiotic formulations are increasingly evaluated as part of a residue-management and antimicrobial-reduction program.

Precision Delivery and Stability Technology

Product efficacy depends on viable cells reaching the intended site of action at a relevant dose. Water-soluble encapsulation of Pediococcus acidilactici using gum Arabic and skim milk improved encapsulation performance, maintained viable counts in an effective range after reconstitution, and preserved antibacterial activity after storage. Microencapsulated Lactobacillus plantarum also achieved better intestinal survival and colonization in layer chicks than non-encapsulated preparations. In a dairy-cow model, compound probiotic microcapsules retained 67.5% survival after simulated gastric exposure and 70.56% viability after 42 days of refrigerated storage.

The practical importance of these systems is that they allow products other than robust Bacillus spores to enter feed applications that were previously inaccessible. Spray drying, freeze drying, coacervation, liposomal systems, nanocoatings, and controlled-release approaches are being developed for different stability and release requirements. Waterline formats, including IFF's Enviva® DUO, can bypass pellet-processing heat altogether. Suppliers that can validate stability through the full feed-manufacturing and delivery chain will be better positioned to capture value from heat-sensitive strains.

Key Restraints

Strain Variability and Dosing Inconsistency

Genus-level labels do not ensure comparable performance. In the 2024 piglet study, feed-conversion differences were statistically significant only in selected trial periods, and immune markers varied materially by day and dosage. Research involving L. plantarum in layer chicks attributed inconsistent outcomes in part to variation in viable cells reaching the intestine after processing, storage, and gastric exposure. This creates a commercial problem: farm managers cannot assume that a strain effective in one production system will yield the same return under different feed matrices, pathogen loads, heat conditions, or treatment histories.

The resulting burden falls most heavily on producers without internal trial capacity. Large integrators can evaluate products across farms and refine protocols; smaller operations may face longer purchasing cycles, dependence on distributor advice, and uncertain repeat-purchase economics. Suppliers that do not provide dose validation, handling guidance, or technical follow-up are more exposed to performance-related attrition.

Fragmented Authorization and Registration Pathways

Regulatory requirements remain a significant cost and timing constraint for novel probiotic products. In the European Union, microbial feed additives require safety and efficacy assessment under Regulation (EC) No 1831/2003, and EFSA updated its efficacy-assessment guidance in July 2024. Existing strains are also subject to renewal requirements, illustrated by the 2024 renewals for Lactiplantibacillus plantarum and Pediococcus acidilactici strains and Enterococcus lactis DSM 22502.

China's Ministry of Agriculture and Rural Affairs maintains the national feed-additive catalog, with Announcement No. 774 in January 2024 approving new feed additives and revising catalog entries. Approval processes can include extended safety monitoring and local documentation requirements. U.S. direct-fed microbial definitions and GRAS expectations, together with differing requirements in Europe, China, India, Brazil, and other markets, raise the cost of managing a global strain portfolio. The effect is to favor companies with regulatory infrastructure and established strain dossiers.

Encapsulation and controlled delivery could reduce that divide, but only if their added formulation cost is offset by more predictable performance. The strategic prize is not simply higher probiotic inclusion; it is the conversion of technically complex products into reliable, scalable farm inputs. Regulatory capability and technical-service coverage will therefore remain as important as strain ownership.

Animal Feed Probiotics Market Segment Analysis

By Product Type

Bacillus holds the largest product-type share at 32% of 2025 value, or USD 84.91 million, and is projected to reach USD 170.87 million by 2035 at a 7.39% CAGR. Its position reflects endospore stability during pelleting, storage, and gut transit. Bacillus subtilis, B. licheniformis, and B. amyloliquefaciens fit existing feed-mill systems and have evidence supporting pathogen exclusion and intestinal-barrier effects in broilers.

Lactobacilli account for 24% of 2025 value, or USD 63.53 million, and are forecast to reach USD 126.78 million at a 7.31% CAGR. Their use is concentrated in liquid feed, poultry waterlines, and premium pet-nutrition applications where viability can be protected. Lallemand's Pediococcus acidilactici CNCM I-4622, marketed as Bactocell, received Great Britain authorization in December 2024 for liquid-feed hygiene across all species.

Saccharomyces and yeast-based preparations represent 14% of 2025 value, or USD 38.02 million, and are projected to grow at an 8.23% CAGR. Their relevance in ruminants and aquaculture stems from multifunctional applications involving fermentation support, immune response, and intestinal health. Lallemand's shrimp trial involving the YANG yeast derivative reported support for immunity, antioxidant defenses, intestinal health, and production performance.

Bifidobacterium represents 8% of 2025 value, or USD 21.97 million, and grows at 8.64% CAGR. Enterococcus holds 10%, or USD 26.09 million, at a 6.79% CAGR; its continued use is moderated by strain-specific regulatory scrutiny, although Enterococcus lactis DSM 22502 was renewed for all species through October 2034. Postbiotics account for 6%, or USD 15.38 million, at a 6.16% CAGR and provide an option where live-cell authorization is restrictive. Streptococcus represents 3%, or USD 8.81 million, but posts the highest product CAGR, at 11.07%, reaching USD 24.80 million by 2035. Other microbial genera account for 3%, or USD 8.60 million, at an 8.45% CAGR.

By Form

Powder and dry products account for 48% of 2025 value, or USD 127.05 million, and are projected to reach USD 253.55 million by 2035 at a 7.31% CAGR. Their dominance reflects low handling costs and compatibility with established blending systems. Microencapsulated products represent 22%, or USD 58.18 million, at a 7.27% CAGR. Their value proposition is linked to preservation of viable cells through processing and delivery, as demonstrated by microencapsulated L. plantarum in poultry.

Liquid and soluble formats account for 14% of 2025 value, or USD 38.02 million, and grow at 8.23% CAGR through waterline, liquid-feed, and aquaculture applications. Granules represent 10%, or USD 27.32 million, at an 8.45% CAGR, with particular relevance to ruminant top-dressing and total mixed rations. Other formats, including freeze-dried and emerging formulations, account for 6%, or USD 16.72 million, and grow at 8.85% CAGR.

By Function

Digestive health and gut integrity account for 34% of 2025 value, or USD 90.26 million, and are projected to reach USD 181.90 million by 2035 at a 7.41% CAGR. Immune support represents 22%, or USD 58.18 million, while growth promotion and feed efficiency account for 18%, or USD 48.72 million; both grow at 8.11% CAGR. Feed-conversion outcomes are increasingly positioned as downstream effects of improved intestinal integrity rather than as direct growth-promotion claims.

Pathogen control and competitive exclusion hold 14% of 2025 value, or USD 38.02 million, and expand at 8.23% CAGR. Stress-management applications account for 7%, or USD 18.06 million, at 6.39% CAGR. Other functions, including methane modulation and nutrient management, represent 5%, or USD 14.07 million, and post the highest functional CAGR at 9.05%. A 2024 meta-analysis found that multi-strain bacterial probiotics associated with reductive acetogenesis and propionate production produced a significant methane reduction in cattle during longer supplementation periods ^{[5]ScienceDirect, sciencedirect.com}.

By Livestock

Poultry leads the market with 38% of 2025 value, or USD 100.95 million, and is expected to reach USD 203.95 million by 2035 at a 7.44% CAGR. Broilers are the principal demand source because short production cycles make feed-conversion and mortality outcomes commercially visible. Swine holds 24%, or USD 63.53 million, at a 7.31% CAGR, with nursery-pig gut health and the phase-out of pharmacological zinc oxide in Europe supporting adoption.

Cattle and ruminants account for 18%, or USD 47.48 million, and grow at 7.18% CAGR. Yeast products and direct-fed microbials are relevant where ruminal fermentation, feed efficiency, and methane reduction are jointly considered ^{[6]Frontiers, frontiersin.org}. Aquaculture represents 10%, or USD 26.09 million, at a 6.79% CAGR. Intensive shrimp production remains a critical opportunity because Vibrio-related disease outbreaks impose major losses across the sector. Pet food accounts for 5%, or USD 13.94 million, and expands at 9.18% CAGR to USD 33.07 million by 2035. Equine applications represent 3%, or USD 8.57 million, and grow at 10.07% CAGR.

By Distribution Channel

Feed mills and integrators account for 56% of 2025 distribution value, or USD 149.07 million, and are projected to reach USD 303.16 million by 2035 at a 7.51% CAGR. Centralized feed procurement allows specifications to be applied across company-owned facilities and contract growers. Veterinary distributors represent 18%, or USD 47.48 million, at a 7.18% CAGR, while direct manufacturer-to-farm sales account for 14%, or USD 37.73 million, at 7.95% CAGR.

Online and e-commerce distribution represents 7%, or USD 19.30 million, and posts the highest channel CAGR, at 8.77%. Growth is concentrated in pet, equine, and small-farm applications where individual owners make purchasing decisions. Other channels, including cooperatives and public distribution programs, account for 5%, or USD 13.73 million, at an 8.38% CAGR.

By End User

Commercial and industrial farms account for 72% of 2025 value, or USD 191.21 million, and are forecast to reach USD 385.84 million by 2035 at a 7.42% CAGR. This group includes integrated poultry and swine operations, feedlots, large dairy farms, commercial aquaculture operations, and contracted outgrowers. Small-scale and backyard operations represent 22%, or USD 59.41 million, at an 8.03% CAGR. Other end users, including institutional purchasers, research facilities, and specialty-feed manufacturers, account for 6%, or USD 16.68 million, and grow at 8.89% CAGR.

Faster growth resides in products that solve a different problem: enabling sensitive strains, premium applications, or alternative delivery models. Liquid, microencapsulated, pet-food, equine, and direct-sale formats command attention because they allow suppliers to compete on strain functionality and technical service rather than only scale. The methane-management category remains early-stage, but its trajectory could become more significant if livestock-emissions frameworks move from experimental programs to commercial procurement incentives.

Animal Feed Probiotics Market Regional Analysis

North America

North America is estimated at USD 54.25 million in 2025 and is projected to reach USD 104.73 million by 2035 at a 6.95% CAGR. The United States accounts for USD 46.92 million, representing 86.5% of regional value and 18.51% of global value. The Veterinary Feed Directive and FDA antimicrobial-use policies have changed the operating context for poultry and swine producers by restricting production uses of medically important antimicrobials. This favors direct-fed microbial programs that can be incorporated into centralized integrator feed specifications.

Canada is estimated at USD 7.33 million in 2025. The region benefits from proximity to major ingredient and animal-nutrition suppliers, including IFF/Danisco, Novus International, Lallemand, and Kemin. Availability of technical support and established feed-manufacturing infrastructure supports adoption, although growth is lower than in less mature regions.

Europe

Europe is valued at USD 80.99 million in 2025 and is forecast to reach USD 159.85 million by 2035 at a 7.19% CAGR. Germany leads the regional market at USD 21.46 million, supported by substantial pig, poultry, and dairy production. Europe's regulatory architecture creates a more formal demand floor for alternatives to antibiotic-based production practices than most other markets.

Regulatory authorization is also a competitive filter. Renewals for Lactiplantibacillus plantarum and Pediococcus acidilactici strains, Levilactobacillus brevis DSM 23231, and Enterococcus lactis DSM 22502, as well as authorization of Bacillus subtilis and Lactococcus lactis combinations for feed hygiene, extend commercial options for approved products. The United Kingdom's separate authorization of Bactocell for liquid-feed hygiene illustrates how post-Brexit regulatory pathways can remain aligned in purpose while operating independently.

Asia Pacific

Asia Pacific is the largest regional market at USD 93.09 million in 2025 and is expected to reach USD 203.95 million by 2035 at an 8.31% CAGR. China contributes USD 32.12 million and remains the region's primary volume market because of its large pork and poultry sectors. MARA's feed-additive catalog process creates a meaningful market-entry barrier; Announcement No. 774 in January 2024 added new feed varieties and additive categories.

China is also drawing targeted investment from multinational suppliers. Evonik and Shandong Vland Biotech introduced their joint-venture portfolio at the China Feed Industry Expo in April 2024, including SpeoCare™ T60 and GutPlus® Virsorb. India's restrictions on antibiotic growth promoters, combined with development of formal commercial feed channels, support demand for biological alternatives. Japan, South Korea, Australia, and Southeast Asian markets provide distinct opportunities in premium livestock, high-density poultry, and shrimp aquaculture. Angel Yeast's 2024 Tibet probiotics facility and USD 43.46 million Indonesian yeast-production investment illustrate the region's growing production footprint ^{[7]Food Ingredients First, foodingredientsfirst.com}.

Latin America

Latin America is valued at USD 23.41 million in 2025 and is projected to reach USD 44.10 million by 2035 at a 6.69% CAGR. Brazil, at USD 6.79 million, is the regional anchor because export-oriented poultry production creates demand for antibiotic-reduction programs aligned with customer and destination-market requirements. Mexico and Argentina provide secondary demand nodes in poultry, swine, and feedlot cattle.

Growth remains below the global average because domestic antimicrobial restrictions are less uniform than in Europe and North America, while imported products can carry tariff, logistics, and pricing burdens. This makes formulation cost and local distribution capability especially important for reaching small and medium-sized producers.

Middle East and Africa

Middle East and Africa is valued at USD 15.56 million in 2025 and is forecast to reach USD 38.58 million by 2035 at a 9.61% CAGR. The United Arab Emirates represents USD 3.73 million and functions as a Gulf distribution and premium-poultry hub. Food-security investment and demand for Halal-certified, antibiotic-reduced production are supporting commercial poultry expansion across the Gulf.

South Africa provides the region's most developed animal-nutrition base. Nutreco's Trouw Nutrition business announced its acquisition of AECI Animal Health in July 2024 to strengthen distribution and manufacturing coverage in Southern Africa ^{[8]Trouw Nutrition, trouwnutrition.com}. Across the rest of sub-Saharan Africa, formal livestock production remains less developed, but rising antimicrobial-resistance awareness and One Health initiatives create a longer-term route to adoption.

Middle East and Africa offers the fastest percentage growth from a smaller base, particularly where poultry capacity expansion and traceability requirements reinforce demand for non-antibiotic production inputs. Latin America remains commercially important but more price sensitive, making local service coverage and lower-cost, stable formulations critical. Suppliers should therefore treat regional strategy as a portfolio of distinct regulatory and delivery models rather than a single global rollout.

Animal Feed Probiotics Market Share & Competitive Landscape

DSM-Firmenich holds the leading share at 12% of 2025 market value, equivalent to approximately USD 32.1 million. Its position reflects the Biomin-derived gut-health portfolio, premix operations, and broader animal-nutrition capabilities. DSM-Firmenich announced the planned separation of its Animal Nutrition & Health business in February 2024. In February 2025, Novonesis agreed to acquire DSM-Firmenich's Feed Enzyme Alliance share for EUR 1.5 billion, while DSM-Firmenich retained its Animal Nutrition & Health premix network as a customer.

Chr. Hansen, now part of Novonesis, holds 10% market share, or approximately USD 26.7 million. The Novozymes-Chr. Hansen combination created a consolidated biosolutions platform spanning enzymes and probiotics. The Feed Enzyme Alliance transaction increases Novonesis' commercial reach in animal biosolutions and reinforces the strategic value of combined enzyme-probiotic offerings ^{[9]Novonesis, novonesis.com}.

Cargill Animal Nutrition holds 8% market share, or approximately USD 21.4 million. Its probiotic exposure is embedded within integrated feed, premix, and nutritional-solution offerings, giving the company access to centralized livestock procurement and contract-feed manufacturing channels.

IFF, through Danisco Animal Nutrition & Health, holds 7% market share, or approximately USD 18.7 million. Its portfolio includes Enviva® PRO, Enviva® DUO, Syncra® AVI, and Syncra® SWI. IFF received EU-wide approval in June 2024 for Syncra® AVI and Axtra® XAP, including what it described as the region's first approved enzyme-probiotic combination for poultry.

Lallemand Animal Nutrition holds 5% market share, or approximately USD 13.4 million. Its offering includes Bactocell, Yela Prosecure, Optiwall, and the LALPROBIOME pet-nutrition platform. The company expanded its regulatory position in Great Britain through Bactocell's liquid-feed-hygiene authorization and established the Biofilm1Health joint laboratory with the Micalis Institute in October 2024.

Alltech participates through its broader nutritional-additives portfolio, including gut-health products such as Acid-Pak 4-Way 2X. Its distribution footprint supports access to emerging livestock markets, including African production systems.

Kemin Industries markets probiotic and gut-health products through a broader animal-nutrition platform. Its manufacturing and ingredient-distribution network supports regional scale where procurement economics and reliable supply are decisive.

Evonik Industries competes through Nutrition & Care and its joint venture with Shandong Vland Biotech. The venture has commercialized gut-health solutions in China, including SpeoCare™ T60 and GutPlus® Virsorb. Evonik also reported that Ecobiol® became the first Bacillus subtilis-based product registered in mainland China's commercial feed-additive catalog.

Novus International operates in gut health, enzymes, and direct-fed microbial-adjacent applications. It partnered with Ginkgo Bioworks in September 2024 to develop next-generation feed additives, announced a co-development partnership with Resilient Biotics for a swine-health solution in January 2025, and acquired BioResource International to expand fermentation and microbiology capabilities.

Lesaffre Group supplies yeast-based animal-nutrition products through Phileo Lesaffre Animal Care, including Actisaf and SafMannan. Its new yeast-production facility in Indonesia, inaugurated in February 2024, strengthens its Asia Pacific supply position.

Angel Yeast is a major Chinese yeast and probiotic producer expanding its international manufacturing footprint. Its Tibet probiotics research and production operation focuses on Lactobacillus plantarum and Streptococcus thermophilus strains, while its Indonesian facility investment supports regional production capacity.

Biomin operates as a DSM-Firmenich Animal Nutrition & Health brand following the acquisition of Erber Group. EW Nutrition acquired Biomin's BIOSTABIL silage-inoculant product line in March 2024, separating that activity from the remaining gut-health portfolio.

Nutreco, through Trouw Nutrition, participates in premium nutritional solutions and functional feed additives. Its planned acquisition of AECI Animal Health strengthens animal-nutrition distribution and manufacturing coverage in South Africa.

MicroSynbiotiX is an Irish biotechnology company developing microalgae-based oral-delivery systems for aquaculture immunization and disease management. Its feed-delivered microalgae platform is directed at shrimp and fish health, including White Spot Syndrome Virus applications. The company represents an early-stage approach that extends beyond conventional probiotic mechanisms.

Recent Industry Developments

February 2025 - Novonesis Acquires DSM-Firmenich's Feed Enzyme Alliance Share

Novonesis announced an agreement on February 11, 2025, to acquire DSM-Firmenich's Feed Enzyme Alliance sales and distribution activities for EUR 1.5 billion in cash. DSM-Firmenich's feed-enzyme business recorded approximately EUR 300 million in annual net sales in 2024.

February 2024 - DSM-Firmenich Begins Animal Nutrition & Health Separation

DSM-Firmenich initiated the separation of its Animal Nutrition & Health business in February 2024. The business had approximately EUR 600 million in annual sales and entered a transaction phase in early 2025.

July 2024 - Nutreco Announces South African Acquisition

Nutreco announced its intention to acquire AECI Animal Health in South Africa through Trouw Nutrition in July 2024. The transaction expands distribution and manufacturing capability in the country.

June 2024 - IFF Receives EU Approval for Poultry Solutions

IFF announced EU-wide regulatory approval for Syncra® AVI and Axtra® XAP in June 2024, expanding its poultry gut-health portfolio across EU member states.

April 2024 - Evonik Vland Biotech Debuts at China Feed Industry Expo

Evonik and Shandong Vland Biotech presented their joint-venture portfolio at the China Feed Industry Expo in April 2024, introducing SpeoCare™ T60 and GutPlus® Virsorb.

March 2024 - EW Nutrition Acquires BIOSTABIL Product Line

EW Nutrition acquired Biomin's BIOSTABIL silage-inoculant product line from DSM-Firmenich effective March 1, 2024.

February 2024 - Lesaffre Opens Indonesian Yeast Plant

Lesaffre inaugurated a 9.8-hectare yeast-production facility in Malang Regency, East Java, in February 2024 to serve Indonesia and ASEAN markets.

December 2024 - Bactocell Authorized for Liquid-Feed Hygiene in Great Britain

Lallemand announced in December 2024 that Bactocell received Food Standards Agency authorization as the first microbial product approved for liquid-feed hygiene across all livestock species in Great Britain.

January 2025 - Novus and Resilient Biotics Enter Swine-Health Partnership

Novus International and Resilient Biotics announced a co-development partnership in January 2025 focused on a new swine-health solution.